The Stem Cell Opportunity: Taking a Stand when It's Too Early
This article was originally published in Start Up
Executive Summary
The degenerative diseases that are the target of new stem cell therapies represent many of the largest unmet clinical needs in medicine today. According to "Tissue Engineering and Cell Transplantation: Technologies, Opportunities, and Evolving Markets in the US, " a report recently published by Medtech Insight, in the future, stem cell therapies will hold a place in numerous markets, each with potential sales in the billions.
You may also be interested in...
Osiris/Genzyme Put Stem Cells On The Deal Map
First-in-class MSC-based therapy Prochymal headed to regulators in 2009 for GvHD.
Stem Cell Therapy Shown Safe For Most Myocardial Infarction Patients
Bioheart expects efficacy data for MyoCell therapy in late 2009.
Stem Cell Summit 2008: Moving from Process to Product
More than 40 companies revealed promising research and clinical results at the 2008 Stem Cell Summit in February. Perhaps most impressive was the number of stem cell therapies already in use or tantalizingly close to market launch.